Holen Sie sich die Stockscreener-App
1.42
5.97%
0.08
Vorhandelsmarkt:
1.45
0.03
+2.11%
Schlusskurs vom Vortag:
$1.34
Offen:
$1.355
24-Stunden-Volumen:
37,863
Relative Volume:
0.89
Marktkapitalisierung:
$4.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.91M
KGV:
-0.1602
EPS:
-8.8661
Netto-Cashflow:
$-10.83M
1W Leistung:
-7.19%
1M Leistung:
-13.94%
6M Leistung:
-62.33%
1J Leistung:
-92.04%
1-Tages-Spanne:
$1.32
$1.42
1-Wochen-Bereich:
$1.07
$1.50
52-Wochen-Spanne:
$1.07
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Firmenname
Silexion Therapeutics Corp
Sektor
Branche
Telefon
972-8-6286005
Adresse
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
1.42 | 4.73M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
Silexion Therapeutics Announces Immediate Board Membership Change - TipRanks
Ilan Levin removed from Silexion Therapeutics board - TradingView
Board at Silexion Therapeutics (NASDAQ: SLXN) removes Ilan Levin - Stock Titan
Is Silexion Therapeutics Corp a strong growth stockMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204 - TipRanks
Silexion Shareholders Reject Capital Increase and Plan Amendments - The Globe and Mail
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Clinical Trial of SIL204 in Advanced Pancreatic Cancer - Minichart
Silexion Therapeutics Receives Approval from Israeli - GlobeNewswire
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - Yahoo! Finance Canada
Silexion gains approval for SIL204 pancreatic cancer trial - TipRanks
Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment - Benzinga
Regulators clear Silexion (NASDAQ: SLXN) to begin SIL204 pancreatic cancer trial - Stock Titan
Pancreatic cancer drug SIL204 gets Israel approval for human trial - Stock Titan
Silexion Therapeutics Corp 8-K Filing – Share Capital Increase Proposal Not Approved (March 2026) - Minichart
Silexion Therapeutics Corp announced plans to submit its Phase 2/3 clinical trial application to German regulators by the end of this quarter. - Bitget
Silexion Therapeutics shareholders reject share capital and equity plan increases By Investing.com - Investing.com South Africa
Shareholders at Silexion (SLXN) vote down capital and evergreen increase proposals - Stock Titan
Growth Report: Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soon2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn
EPS Watch: Can Silexion Therapeutics Corp Equity Warrant expand its profit margins2026 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Form 8K Silexion Therapeutics Corp For: 3 February - Investing.com
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Tangible book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
SLXNW Financials: Income Statement, Balance Sheet & Cash Flow | Silexion Therapeutics Corp - Stock Titan
Silexion Therapeutics Corp: Clinical-Stage KRAS Oncology Innovations and siRNA Pipeline for Pancreatic Cancer - Minichart
Silexion Therapeutics Reports 2025 Financial Results and Clinical Program Updates - geneonline.com
Biotech Silexion lines up 2026 pancreatic cancer trial after $18.6M cash raise - Stock Titan
Silexion Therapeutics 10-K: $11.9M net loss, cash $6.08M; operating loss $11.63M - TradingView
Silexion Therapeutics (NASDAQ: SLXN) outlines SIL204 KRAS cancer strategy in 10-K - Stock Titan
Silexion Therapeutics Corp Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Growth Recap: Is Silexion Therapeutics Corp Equity Warrant a potential multi baggerTrade Volume Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Setup Watch: Can Silexion Therapeutics Corp Equity Warrant stock outperform in a bear marketBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Silexion Therapeutics Corp Auditor Raises 'Going Concern' Doubt - marketscreener.com
SLXN SEC FilingsSilexion Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: MetaVia (MTVA), Immunome (IMNM) - The Globe and Mail
Fed Meeting: Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soonQuarterly Profit Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting - Bitget
Cancer biotech Silexion seeks to authorize 50M more shares - Stock Titan
Rally Mode: Is Silexion Therapeutics Corp a defensive stock2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
SLXN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
EPS Watch: Is First Light Acquisition Group Inc Equity Warrant vulnerable to short sellersQuarterly Portfolio Report & Smart Allocation Stock Tips - baoquankhu1.vn
SLXN Should I Buy - Intellectia AI
EBITDA per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Market Fear: Should value investors consider CompoSecure Inc Equity WarrantMarket Activity Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Equity grants to director-linked fund at Silexion Therapeutics (SLXN) disclosed - Stock Titan
Director Alon Ruth receives Silexion (SLXN) share and stock option grants - Stock Titan
Silexion Therapeutics (SLXN) CFO receives 49,726-share equity grant - Stock Titan
Silexion (SLXN) CEO Hadar Ilan receives 64,350-share equity award - Stock Titan
Director at Silexion Therapeutics (SLXN) receives new share and option grants - Stock Titan
Silexion Therapeutics (SLXN) director granted 7,576 shares and 8,904 options - Stock Titan
Finanzdaten der Silexion Therapeutics Corp-Aktie (SLXN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):